Hjem › Kastringsresistent prostatakræft
Kastringsresistent prostatakræft kliniske forsøg rekrutterer i USA
18 studier for Kastringsresistent prostatakræft rekrutterer deltagere på steder over hele USA.
Byer med flest studier
- Los Angeles, CA8 studier
- New York City, NY7 studier
- Seattle, WA6 studier
- Houston, TX6 studier
- Boston, MA5 studier
- Queens, NY4 studier
- Pittsburgh, PA4 studier
- Philadelphia, PA4 studier
- Mountain View, CA3 studier
- San Francisco, CA3 studier
- Dallas, TX3 studier
- Minneapolis, MN3 studier
- Cincinnati, OH3 studier
- Nashville, TN3 studier
- St. Louis, MO3 studier
- Baltimore, MD3 studier
- Grand Rapids, MI3 studier
- Myrtle Beach, SC3 studier
- San Diego, CA3 studier
- Arlington, VA3 studier
- Metairie, LA3 studier
Efter delstat
- Californien11 studier
- Connecticut3 studier
- Florida5 studier
- Illinois3 studier
- Louisiana3 studier
- Maryland3 studier
- Massachusetts5 studier
- Michigan7 studier
- Minnesota4 studier
- Missouri3 studier
- Nebraska3 studier
- New Jersey4 studier
- New York8 studier
- North Carolina4 studier
- Ohio4 studier
- Oregon3 studier
- Pennsylvania5 studier
- South Carolina4 studier
- Tennessee5 studier
- Texas7 studier
- Virginia4 studier
- Washington6 studier
Nyligt opdaterede studier
Officiel studietekst (engelsk)
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07225946A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
RekruttererFase 3
Alder 18 og opefter · Mænd · Opdateret 25. sep. 2026 · NCT07164443A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
RekruttererFase 1
Alder 18 og opefter · Mænd · Opdateret 24. sep. 2026 · NCT07719361A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2026 · NCT06863272Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2026 · NCT06353386Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
RekruttererFase 1
Alder 18 og opefter · Mænd · Opdateret 10. sep. 2026 · NCT05997615A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 19. aug. 2026 · NCT04104776Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RekruttererFase 1
Alder 18 til 100 · Mænd · Opdateret 13. aug. 2026 · NCT05519449A Study of MGC026 in Participants With Advanced Solid Tumors
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 11. aug. 2026 · NCT06242470A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
RekruttererFase 1
Alder 18 og opefter · Mænd · Opdateret 10. aug. 2026 · NCT06067841A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
RekruttererObservationsstudie
Alder 18 til 115 · Mænd · Opdateret 16. jul. 2026 · NCT07677267A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer
RekruttererObservationsstudie
Alder 18 til 115 · Mænd · Opdateret 16. jul. 2026 · NCT07677254A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
RekruttererFase 1/2
Alder 18 og opefter · Mænd · Opdateret 29. maj 2026 · NCT0725840764Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
RekruttererFase 1/2
Alder 18 og opefter · Mænd · Opdateret 6. maj 2026 · NCT04868604Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
RekruttererFase 2
Alder 18 og opefter · Mænd · Opdateret 13. apr. 2026 · NCT04337580Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
RekruttererFase 1/2
Alder 18 og opefter · Mænd · Opdateret 13. apr. 2026 · NCT06190899Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
RekruttererFase 1
Alder 18 og opefter · Mænd · Opdateret 21. nov. 2025 · NCT0574362118F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
RekruttererFase 4
Alder 18 og opefter · Mænd · Opdateret 27. nov. 2024 · NCT06706921Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.